Recently in this Journal, de Die-Smulders et all reported a father and son both affected with BPES (blepharophimosis, ptosis, epicanthus inversus syndrome) and carrying a balanced 3; 1(q21;q23) translocation in the absence of mental retardation. These findings provided new evidence for the location of the BPES gene at 3q2, as previously suggested by Fukushima et al,2 who reported an infant carrying a de novo translocation involving the 3q23 region.
We report on a young girl with mild mental retardation, blepharophimosis, ptosis, telecanthus, epicanthus inversus, and a de novo apparently balanced 3;8(q23;p21.1) translocation (fig 1) Couple screening has been said to be superior to stepwise screening because carriers whose partner's test result is negative are not made anxious while awaiting their partner's result, nor by the knowledge that their risk is higher than it was before they were tested (pretest risk of having affected child 1/2500, post partner test risk 1/600). However, it does not allow relatives of identified carriers to be informed of their increased carrier risk, nor does it alert detected carriers of their risk with new partners.4
We propose an alternative form of couple screening (disclosure couple screening) that circumvents these disadvantages: carrier testing is only performed if a DNA sample is provided by each partner but carrier test results are fully disclosed to the couple. If one partner is found to be a carrier the other's sample is immediately available for analysis, therefore both partners' results can be imparted simultaneously, allowing couples at low risk of having an affected child to be counselled about their carrier status. Either or both samples could be tested as long as patients were fully informed which samples were tested.
We believe that disclosure couple prenatal screening may decrease test associated anxiety without altering the uptake rate of screening. It may be that an informed carrier woman will be more likely to assign paternity correctly than one who is unaware of her carrier status. As with any genetic test, good pretest counselling is essential. Full evaluation is necessary before any method of screening becomes routine practice. 
